Alumis jumps after skin disease drug meets main goal in late-stage trials

Shares of biopharma firm Alumis ALMS.O jump 17.2% to $9.74 premarket

ALMS says its experimental pill, envudeucitinib, met the main goal in two late-stage studies in patients with moderate-to-severe plaque psoriasis

In both the trials, envudeucitinib showed clearer skin compared to placebo after 24 weeks of treatment

Plaque psoriasis is an immune‑mediated skin disease where the immune system becomes overactive and causes skin cells to grow too quickly

Alumis plans to submit a marketing application to the U.S. FDA in H2 2026

In the last 12 months, stock down 14.9% YTD